# Role of specialized pro-resolving mediators of inflammation resolution in emphysema:  analyses of SPIROMICS and LEEP

> **NIH NIH R21** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $139,088

## Abstract

Project Summary/Abstract
Inflammation is a central pathologic mechanism across a variety of chronic diseases, including cardiovascular,
metabolic, and pulmonary disorders. Current approaches to disease management center on non-specific
strategies to attenuate local and systemic inflammation to improve health outcomes. However, emerging data
supports the presence of endogenous mechanisms increasing an individual’s capacity to resolve inflammation,
highlighting a yet untapped novel therapeutic target. New insights into the resolution of inflammation reveal this
process can be mediated by lipid-derived specialized pro-resolving mediators (SPMs), which trigger a cascade
of events that attenuate the inflammatory response. SPMs have been implicated in the resolution of
inflammation in a variety of diseases such as cardiovascular disease, COVID-19, and asthma; however, their
role in resolving inflammation and counteracting lung injury in COPD patients is unknown. The objective of this
proposal is to determine if greater plasma circulating SPM concentrations (reflecting individual capacity to
resolve inflammation) are associated with improved respiratory outcomes in individuals with emphysema. To
accomplish this, we will leverage data from the robustly-phenotyped and diverse Subpopulations and
Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort with available biospecimens in
BIOLINCC. We will then validate our findings in The Losartan Effects on Emphysema Progression (LEEP)
cohort. This proposal will accomplish the following specific aims: in SA 1: we will characterize circulating SPM
concentrations as a biomarker for decreased potential to resolve chronic inflammation across two diverse
populations of emphysema patients and identify risk factors (e.g.race/ethnicity, economic deprivation, etc.) for
low SPM status. We hypothesize that there will be clear disparities in SPM across subpopulations reflecting
differences in resilience to inflammatory insults. In SA 2: we will determine the association between circulating
SPM concentrations and COPD health outcomes (i.e., lung function, respiratory symptoms) across two
populations of emphysema patients. We hypothesize that greater SPM status will be associated with greater
lung function and decreased respiratory morbidity. This work is directly related to the mission of NHLBI as it will
provide foundational evidence for SPMs as an emerging therapeutic target for the prevention and treatment of
COPD, stimulating basic discoveries about the causes of, and resilience factors for, lung disease and enabling
the translation of these findings into clinical practice.

## Key facts

- **NIH application ID:** 10972838
- **Project number:** 1R21HL175177-01
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Sonali Bose
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $139,088
- **Award type:** 1
- **Project period:** 2024-08-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10972838

## Citation

> US National Institutes of Health, RePORTER application 10972838, Role of specialized pro-resolving mediators of inflammation resolution in emphysema:  analyses of SPIROMICS and LEEP (1R21HL175177-01). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10972838. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*